Lung Cancer
A Phase III, Randomized, Open-label Study of Izalontamab Brengitecan (BMS-986507) in Combination with Osimertinib versus Osimertinib Monotherapy or Osimertinib in Combination with Platinum-based Chemotherapy as First-Line Therapy in Patients with EGFR-Mutant Locally Advanced or Metastatic Non-small Cell Lung Cancer (CA244-0020)
- Details
ClinicalTrials.gov ID:
NCT07680790
Diagnosis Type:
NA
USOR Number:
- Address
,
P: